In my last Seeking Alpha article Athersys: Abundance of Opportunity, I gave an overview of the company, highlighted the late-stage programs under development, and offered my views on potential upcoming catalysts. The four months since the publishing of that article has seen an unfortunate ramping up of a worldwide pandemic, social unrest, and political turmoil. Throughout all of this, Athersys has continued to advance the development of its novel, allogeneic cell therapy MultiStem for key acute care indications. For my follow-up article, I will provide an update on their two late-stage programs in ARDS